by Truveta staff | May 28, 2024 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) increased throughout the first quarter of 2024 (+20.9% increase in March 2024 compared to December 2023). First-time prescribing rates (first-time GLP-1 RA prescriptions per total...
by Truveta Research | Nov 27, 2023 | Research, Research Insights
Today Truveta announced new comparative effectiveness research exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro). Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1...
